Pharmaceutical

Dalfampridine IR by Solaxa for Spinocerebellar Ataxia (SCA): Likelihood of Approval

Dalfampridine IR is under clinical development by Solaxa and currently in Phase II for Spinocerebellar Ataxia (SCA).

Jul 6, 2024 - 04:00
Dalfampridine IR is under clinical development by Solaxa and currently in Phase II for Spinocerebellar Ataxia (SCA).
Read the original article

Tags:

Previous Article

LP-184 by Starlight Therapeutics for Non-Small Cell Lung Cancer: Likelihood of A...

Next Article

AZD-2389 by AstraZeneca for Metabolic Dysfunction-Associated Steatohepatitis (MA...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharma executives shower Bill Cassidy with campaign cash

STAT+: Pharma executives shower Bill Cassidy with campa...

Apr 27, 2023

Colorado could cap payments for Amgen’s Enbrel

Colorado could cap payments for Amgen’s Enbrel

Feb 23, 2024

STAT+: Survey: Confusion over key requirements means clinical trials aren’t registered and results aren’t reported

STAT+: Survey: Confusion over key requirements means cl...

Jan 16, 2024